#160724

Caki-2 SETD2 KO cell line

Cat. #160724

Caki-2 SETD2 KO cell line

Cat. #: 160724

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Kidney

Model: Knock-Out

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Sergio F de Almeida

Institute: Instituto de Medicina Molecular Jo?„ƒo Lobo Antunes

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Caki-2 SETD2 KO cell line
  • Alternate name: HBP231, HIF-1, HIP-1, HYPB, KMT3A
  • Research fields: Cancer;Genetics
  • Tool sub type: Continuous
  • Parental cell: Clear cell renal cell carcinoma cell line (Caki-2)
  • Organism: Human
  • Tissue: Kidney
  • Model: Knock-Out
  • Conditional: No
  • Description: Experimental ablation of SETD2 gene expression using the CRISPR/Cas9 system renders Caki-2-SETD2 knockout cells a valuable tool to investigate the role of H3K36me3 histone methylation in processes such as transcription or DNA repair.
  • Production details: CRISPR/Cas9 KO
  • Additional notes: Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Ca...
  • Recommended controls: Caki-2 Parental Line

Target Details

  • Target: SET domain containing 2

Applications

  • Application notes: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796 This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

Handling

  • Format: Frozen
  • Growth medium: Grow as monolayers in Dulbecco's modified Eagle medium, supplemented with 10% (v/v) FBS, 1% (v/v) nonessential amino acids, 1% (v/v) L-glutamine and 100U/mL penicillin-streptomycin, at 37?‚°C in a humidified atmosphere with 5% CO2.
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

Related Tools

  • Related tools: Caki-2 DNMT3A KO cell line

References

  • de Matos et al. 2019. Cancers (Basel). 11(3):. PMID: 30897760.